Timothy Eugene Sullivan, CFO of Apellis Pharmaceuticals ($APLS), sold shares on the open market six times in the last 365 days, totaling $1.84 million. His most recent sale occurred on January 22, 2026. These $APLS insider sales rank 3,665th among 11,678 individual insiders in our database, where the average is $8.6 million across 6.37 transactions. Sullivan made no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 28, 2026 | Apellis Pharmaceuticals, Inc. | $APLS | Sullivan Timothy Eugene | Chief Financial Officer | A | Common Stock | 58140 | $0.00 | 212,437.0000 | 130,067,000 | 37.68% | 0.04% |
| Jan. 22, 2026 | Apellis Pharmaceuticals, Inc. | $APLS | Sullivan Timothy Eugene | Chief Financial Officer | S | Common Stock | 10287 | $21.77 | 154,297.0000 | 130,067,000 | 6.25% | 0.01% |
| Jan. 20, 2026 | Apellis Pharmaceuticals, Inc. | $APLS | Sullivan Timothy Eugene | Chief Financial Officer | S | Common Stock | 2892 | $19.79 | 164,584.0000 | 130,067,000 | 1.73% | 0.00% |
| Jan. 13, 2026 | Apellis Pharmaceuticals, Inc. | $APLS | Sullivan Timothy Eugene | Chief Financial Officer | S | Common Stock | 3856 | $22.19 | 167,476.0000 | 130,067,000 | 2.25% | 0.00% |
| Oct. 21, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Sullivan Timothy Eugene | Chief Financial Officer | S | Common Stock | 10000 | $28.03 | 171,332.0000 | 130,067,000 | 5.51% | 0.01% |
| Oct. 21, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Sullivan Timothy Eugene | Chief Financial Officer | M | Stock Option (Right to Buy) | 10000 | $0.00 | 232,903.0000 | 130,067,000 | 4.12% | 0.01% |
| Oct. 21, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Sullivan Timothy Eugene | Chief Financial Officer | M | Common Stock | 10000 | $10.03 | 181,332.0000 | 130,067,000 | 5.84% | 0.01% |
| Sept. 8, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Sullivan Timothy Eugene | Chief Financial Officer | S | Common Stock | 32729 | $27.86 | 171,332.0000 | 123,905,000 | 16.04% | 0.03% |
| Sept. 8, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Sullivan Timothy Eugene | Chief Financial Officer | M | Common Stock | 15000 | $10.03 | 204,061.0000 | 123,905,000 | 7.93% | 0.01% |
| Sept. 8, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Sullivan Timothy Eugene | Chief Financial Officer | M | Stock Option (Right to Buy) | 15000 | $0.00 | 242,903.0000 | 123,905,000 | 5.82% | 0.01% |
| Sept. 8, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Sullivan Timothy Eugene | Chief Financial Officer | S | Common Stock | 10000 | $27.83 | 171,332.0000 | 123,905,000 | 5.51% | 0.01% |
| June 9, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Sullivan Timothy Eugene | Chief Financial Officer | A | Stock Option (Right to Buy) | 82500 | $19.39 | 82,500.0000 | 123,905,000 | 9999.99% | 0.07% |
| Jan. 29, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Sullivan Timothy Eugene | Chief Financial Officer | S | Common Stock | 546 | $29.52 | 199,061.0000 | 123,905,000 | 0.27% | 0.00% |
| Jan. 22, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Sullivan Timothy Eugene | Chief Financial Officer | S | Common Stock | 3088 | $30.43 | 199,607.0000 | 123,905,000 | 1.52% | 0.00% |
| Jan. 17, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Sullivan Timothy Eugene | Chief Financial Officer | S | Common Stock | 1730 | $29.96 | 156,766.0000 | 123,905,000 | 1.09% | 0.00% |
| Jan. 21, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Sullivan Timothy Eugene | Chief Financial Officer | A | Common Stock | 45929 | $0.00 | 202,695.0000 | 123,905,000 | 29.30% | 0.04% |
| Jan. 13, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Sullivan Timothy Eugene | Chief Financial Officer | S | Common Stock | 2170 | $28.70 | 158,496.0000 | 123,905,000 | 1.35% | 0.00% |
| Dec. 31, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Sullivan Timothy Eugene | Chief Financial Officer | M | Common Stock | 1042 | $14.95 | 150,612.0000 | 124,234,000 | 0.70% | 0.00% |
| Dec. 31, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Sullivan Timothy Eugene | Chief Financial Officer | M | Common Stock | 10054 | $13.85 | 160,666.0000 | 124,234,000 | 6.68% | 0.01% |
| Dec. 31, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Sullivan Timothy Eugene | Chief Financial Officer | M | Stock Option (Right to Buy) | 1042 | $0.00 | 23,958.0000 | 124,234,000 | 4.17% | 0.00% |
| Dec. 31, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Sullivan Timothy Eugene | Chief Financial Officer | M | Stock Option (Right to Buy) | 10054 | $0.00 | 84,946.0000 | 124,234,000 | 10.58% | 0.01% |
| April 18, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Sullivan Timothy Eugene | Chief Financial Officer | G | Common Stock | 14164 | $0.00 | 149,570.0000 | 118,678,000 | 10.46% | 0.01% |
| April 18, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Sullivan Timothy Eugene | Chief Financial Officer | G | Common Stock | 14164 | $0.00 | 149,570.0000 | 118,678,000 | 8.65% | 0.01% |
| April 1, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Sullivan Timothy Eugene | Chief Financial Officer | M | Stock Option (Right to Buy) | 4000 | $0.00 | 257,903.0000 | 118,678,000 | 1.53% | 0.00% |
| April 1, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Sullivan Timothy Eugene | Chief Financial Officer | S | Common Stock | 4000 | $58.66 | 149,570.0000 | 118,678,000 | 2.60% | 0.00% |
| April 1, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Sullivan Timothy Eugene | Chief Financial Officer | M | Common Stock | 4000 | $10.03 | 153,570.0000 | 118,678,000 | 2.67% | 0.00% |
| March 1, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Sullivan Timothy Eugene | Chief Financial Officer | S | Common Stock | 4000 | $62.86 | 151,570.0000 | 118,678,000 | 2.57% | 0.00% |
| March 1, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Sullivan Timothy Eugene | Chief Financial Officer | M | Stock Option (Right to Buy) | 6000 | $0.00 | 261,903.0000 | 118,678,000 | 2.24% | 0.01% |
| March 1, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Sullivan Timothy Eugene | Chief Financial Officer | S | Common Stock | 2000 | $63.95 | 149,570.0000 | 118,678,000 | 1.32% | 0.00% |
| March 1, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Sullivan Timothy Eugene | Chief Financial Officer | M | Common Stock | 6000 | $10.03 | 155,570.0000 | 118,678,000 | 4.01% | 0.01% |
| Feb. 12, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Sullivan Timothy Eugene | Chief Financial Officer | S | Common Stock | 1431 | $67.77 | 149,570.0000 | 118,678,000 | 0.95% | 0.00% |
| Jan. 29, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Sullivan Timothy Eugene | Chief Financial Officer | S | Common Stock | 906 | $64.14 | 151,001.0000 | 118,678,000 | 0.60% | 0.00% |
| Jan. 22, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Sullivan Timothy Eugene | Chief Financial Officer | S | Common Stock | 3551 | $65.00 | 151,907.0000 | 118,678,000 | 2.28% | 0.00% |
| Jan. 16, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Sullivan Timothy Eugene | Chief Financial Officer | A | Common Stock | 23748 | $0.00 | 157,693.0000 | 118,678,000 | 17.73% | 0.02% |
| Jan. 16, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Sullivan Timothy Eugene | Chief Financial Officer | A | Stock Option (Right to Buy) | 34533 | $66.30 | 34,533.0000 | 118,678,000 | 9999.99% | 0.03% |
| Jan. 16, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Sullivan Timothy Eugene | Chief Financial Officer | S | Common Stock | 2235 | $66.81 | 155,458.0000 | 118,678,000 | 1.42% | 0.00% |
| Nov. 30, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Sullivan Timothy Eugene | Chief Financial Officer | M | Common Stock | 14158 | $10.03 | 148,103.0000 | 106,114,000 | 10.57% | 0.01% |
| Nov. 30, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Sullivan Timothy Eugene | Chief Financial Officer | S | Common Stock | 13858 | $54.73 | 134,245.0000 | 106,114,000 | 9.36% | 0.01% |
| Nov. 30, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Sullivan Timothy Eugene | Chief Financial Officer | S | Common Stock | 300 | $54.79 | 133,945.0000 | 106,114,000 | 0.22% | 0.00% |
| Nov. 30, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Sullivan Timothy Eugene | Chief Financial Officer | M | Stock Option (Right to Buy) | 14158 | $0.00 | 267,903.0000 | 106,114,000 | 5.02% | 0.01% |
| July 3, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Sullivan Timothy Eugene | Chief Financial Officer | M | Stock Option (Right to Buy) | 6779 | $0.00 | 282,061.0000 | 106,114,000 | 2.35% | 0.01% |
| July 3, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Sullivan Timothy Eugene | Chief Financial Officer | S | Common Stock | 300 | $91.10 | 133,945.0000 | 106,114,000 | 0.22% | 0.00% |
| July 3, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Sullivan Timothy Eugene | Chief Financial Officer | S | Common Stock | 3287 | $90.42 | 134,245.0000 | 106,114,000 | 2.39% | 0.00% |
| July 3, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Sullivan Timothy Eugene | Chief Financial Officer | S | Common Stock | 3192 | $89.41 | 137,532.0000 | 106,114,000 | 2.27% | 0.00% |
| July 3, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Sullivan Timothy Eugene | Chief Financial Officer | M | Common Stock | 6779 | $10.03 | 140,724.0000 | 106,114,000 | 5.06% | 0.01% |
| June 5, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Sullivan Timothy Eugene | Chief Financial Officer | S | Common Stock | 30506 | $89.83 | 133,945.0000 | 106,114,000 | 18.55% | 0.03% |
| June 5, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Sullivan Timothy Eugene | Chief Financial Officer | M | Stock Option (Right to Buy) | 69779 | $0.00 | 288,840.0000 | 106,114,000 | 19.46% | 0.07% |
| June 5, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Sullivan Timothy Eugene | Chief Financial Officer | M | Common Stock | 69779 | $10.03 | 203,724.0000 | 106,114,000 | 52.10% | 0.07% |
| June 5, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Sullivan Timothy Eugene | Chief Financial Officer | S | Common Stock | 1600 | $90.60 | 202,124.0000 | 106,114,000 | 0.79% | 0.00% |
| June 5, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Sullivan Timothy Eugene | Chief Financial Officer | S | Common Stock | 30609 | $87.79 | 171,515.0000 | 106,114,000 | 15.14% | 0.03% |
| June 5, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Sullivan Timothy Eugene | Chief Financial Officer | S | Common Stock | 7064 | $88.36 | 164,451.0000 | 106,114,000 | 4.12% | 0.01% |
| May 3, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Sullivan Timothy Eugene | Chief Financial Officer | G | Common Stock | 20000 | $0.00 | 133,945.0000 | 106,114,000 | 17.55% | 0.02% |
| May 3, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Sullivan Timothy Eugene | Chief Financial Officer | G | Common Stock | 20000 | $0.00 | 133,945.0000 | 106,114,000 | 12.99% | 0.02% |
| April 19, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Sullivan Timothy Eugene | Chief Financial Officer | G | Common Stock | 36232 | $0.00 | 133,945.0000 | 106,114,000 | 21.29% | 0.03% |
| April 19, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Sullivan Timothy Eugene | Chief Financial Officer | G | Common Stock | 36232 | $0.00 | 133,945.0000 | 106,114,000 | 37.08% | 0.03% |
| Feb. 21, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Sullivan Timothy Eugene | Chief Financial Officer | A | Common Stock | 11683 | $0.00 | 134,919.0000 | 106,114,000 | 9.48% | 0.01% |
| Feb. 21, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Sullivan Timothy Eugene | Chief Financial Officer | F | Common Stock | 974 | $58.50 | 133,945.0000 | 106,114,000 | 0.72% | 0.00% |
| Feb. 21, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Sullivan Timothy Eugene | Chief Financial Officer | A | Stock Option (Right to Buy) | 16572 | $0.00 | 16,572.0000 | 106,114,000 | 9999.99% | 0.02% |
| Feb. 10, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Sullivan Timothy Eugene | Chief Financial Officer | F | Common Stock | 975 | $51.21 | 123,236.0000 | 106,114,000 | 0.78% | 0.00% |
| Jan. 27, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Sullivan Timothy Eugene | Chief Financial Officer | F | Common Stock | 551 | $52.77 | 124,211.0000 | 106,114,000 | 0.44% | 0.00% |
| Jan. 20, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Sullivan Timothy Eugene | Chief Financial Officer | F | Common Stock | 2379 | $52.05 | 124,762.0000 | 106,114,000 | 1.87% | 0.00% |
| Jan. 12, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Sullivan Timothy Eugene | Chief Financial Officer | A | Common Stock | 27488 | $0.00 | 127,141.0000 | 106,114,000 | 27.58% | 0.03% |
| April 25, 2022 | Apellis Pharmaceuticals, Inc. | $APLS | Sullivan Timothy Eugene | Chief Financial Officer | J | Common Stock | 3750 | $0.00 | 99,653.0000 | 0 | 3.63% | 0.00% |
| April 25, 2022 | Apellis Pharmaceuticals, Inc. | $APLS | Sullivan Timothy Eugene | Chief Financial Officer | J | Stock Option (Right to Buy) | 22500 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Jan. 12, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Sullivan Timothy Eugene | Chief Financial Officer | A | Stock Option (Right to Buy) | 43183 | $52.66 | 43,183.0000 | 106,114,000 | 9999.99% | 0.04% |